Journal of the American College of Clinical Pharmacy : JACCP最新文献

{"title":"Evaluation of PHARM-HF, a pharmacist-led heart failure medication titration clinic: A pre-post study","authors":"Simroop Ladhar B.Sc,&nbsp;Nathaniel M. Hawkins MBChB, M.D., MPH,&nbsp;Sean A. Virani M.D., M.Sc., MPH,&nbsp;Ricky D. Turgeon Pharm.D.","doi":"10.1002/jac5.1920","DOIUrl":"10.1002/jac5.1920","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>The PHARM-HF clinic is a novel, pharmacist-led medication optimization clinic for patients with heart failure with reduced ejection fraction (HFrEF). PHARM-HF aims to achieve maximum-tolerated HFrEF guideline-directed medical therapy (GDMT) as outlined by the latest Canadian Cardiovascular Society heart failure guidelines.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective pre-post study evaluated consecutive patients attending PHARM-HF (January 2021–August 2022). The primary outcome was the modified Optimal Medication Therapy (mOMT) score, an aggregate score of HFrEF quadruple therapy. The mOMT score was categorized as suboptimal (score 0–4), acceptable (score 5–7), or optimal (score 8; all four drugs at maximum tolerated dose). Secondary outcomes included change in left ventricular ejection fraction (LVEF) from baseline to 1 year, and Kansas City Cardiomyopathy Questionnaire-12 (KCCQ; range 0 [worst] to 100 [best]) from baseline to discharge.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 81 included patients, median age was 68 years, 21% were female, 61% had New York Heart Association (NYHA) class 2 functional capacity, and median LVEF was 30%. Median mOMT improved from 6 (interquartile range [IQR] 4–7) at baseline to 8 (IQR 7–8) at clinic discharge (<i>p</i> &lt; 0.001; increase from 7% to 73% categorized as optimal). LVEF improved from a median of 30% to 38% at 1 year (<i>p</i> &lt; 0.001). Among 16 patients who completed the KCCQ-12 at both time points, the score was 62 at baseline and 77 at discharge (<i>p</i> = 0.42).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Uptake of GDMT significantly increased from admission to discharge from the PHARM-HF medication optimization clinic, during which other cardiovascular clinicians did not modify HFrEF medications. Furthermore, there was an improvement in LVEF at 1 year. A pilot randomized controlled trial is currently underway to guide the development of a multicenter trial to provide definitive evidence for the role of pharmacist-led medication optimization in HFrEF.</p>\u0000 </section>\u0000 </div>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jac5.1920","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139610047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of the Core Outcome Set for Psychiatric Pharmacists","authors":"Kristina Reinstatler Pharm.D., MBA,&nbsp;Gregory H. Payne MBA,&nbsp;Jonathan F. Lister Pharm.D.,&nbsp;Tera D. Moore Pharm.D.,&nbsp;Brittany L. Parmentier Pharm.D., MPH,&nbsp;Ranel Troy Santos Pharm.D.,&nbsp;Carla D. Cobb Pharm.D.","doi":"10.1002/jac5.1917","DOIUrl":"10.1002/jac5.1917","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The American Association of Psychiatric Pharmacists (AAPP) sought to develop a consensus-based set of outcomes and measures to standardize psychiatric pharmacy practice and research. The measures in this Core Outcome Set for Psychiatric Pharmacists (COS-PP) are designed to study the impact of psychiatric pharmacists caring for individuals living with psychiatric disorders.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The COS-PP was developed using guidelines from the Core Outcome Measures in Effectiveness Trials (COMET) initiative. A committee systematically reviewed a catalog of 194 articles and 40 posters that referenced psychiatric disorders, patient-level outcomes, and pharmacist interventions. From these initial 234 resources, 554 combinations of outcomes and measures were identified. Additional papers, guidelines, and feedback from experts increased the number to 592 combined outcomes and measures. The principal investigator consolidated the list to 46 potential outcomes. AAPP members were invited to complete a survey rating the 46 potential outcomes on five key factors: comprehensive, attributable to pharmacy, feasible, scientifically sound, and usable. These survey results were provided to the 18 Board-Certified Psychiatric Pharmacists participating in a summit examining the potential outcomes and measures gleaned from literature review. Through discussion and refinement, consensus was achieved on the final COS-PP.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The final COS-PP included 21 outcomes, 14 of which included at least 1 measure (84 total measures). The outcomes were grouped according to the quadruple health care aims: better care, reduced healthcare costs, improved patient experience, and improved clinician well-being.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>COS-PP will help define psychiatric pharmacists' support of the interdisciplinary team in addressing the quadruple health care aims. Using standardized outcomes across practice sites will allow aggregation of data on the impact of psychiatric pharmacists on patient care.</p>\u0000 </section>\u0000 </div>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jac5.1917","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139528016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of a psychiatric pharmacist consultation service in a multispecialty outpatient clinic","authors":"Deni Hui Pharm.D.,&nbsp;Dina Chibli Pharm.D.,&nbsp;Samantha Catanzano Pharm.D.","doi":"10.1002/jac5.1921","DOIUrl":"10.1002/jac5.1921","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Integrated care programs provide both medical and mental health care in clinical settings. Psychiatric pharmacists play a key role in optimizing patient care when integrated into a healthcare team. This project describes the implementation and trends of a psychiatric pharmacist consultation service in a multispecialty outpatient through an integrated behavioral healthcare model.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This is a retrospective study analyzing a psychiatric pharmacist consultation service at an academic multispecialty outpatient clinic. Eligible patients were aged ≥17 years and seen by the psychiatric pharmacist between June 1, 2019 and June 30, 2022. Patient demographics, reasons for referral, and pharmacist interventions were collected. Patient outcomes on depression, anxiety, and diabetes were also explored. Descriptive statistics were used to quantify information.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 572 encounters were identified. Of those, 285 (49.8%) represented unique patients. Over the 36-month period, an average of 16 consults were conducted per month. Anxiety and depressive disorders, pain syndromes, and adult attention-deficit/hyperactivity disorder were the most common diagnoses listed as reasons for consultation. An average of five recommendations or interventions were provided by the psychiatric pharmacist at each initial consultation. Anxiety and depression symptom scores, as well as hemoglobin A1c (HbA1c) values, were lower following pharmacist consultation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Psychiatric pharmacists can serve a unique role at multispecialty clinics by providing consultation for patients with psychiatric conditions, chronic pain, medical conditions, and polypharmacy. This study demonstrates the successful utilization of such a service and suggests a psychiatric pharmacist's expertise contributes to improved depression, anxiety, and glycemic outcomes. The multispecialty outpatient setting represents an opportunity to further explore growth for psychiatric pharmacists and the impact these services have on patient outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139530170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating a novel pharmacist-led buprenorphine outreach service for treatment of opioid use disorder in individuals residing in supportive housing","authors":"Janice Ly Pharm.D.,&nbsp;Damian Peterson Pharm.D.,&nbsp;Michelle Geier Pharm.D.","doi":"10.1002/jac5.1915","DOIUrl":"10.1002/jac5.1915","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>In San Francisco, there were 638 accidental overdose deaths involving opioids in 2022 alone, with opioid overdoses occurring at a disproportionate rate in the Black population and in those with fixed housing. Past studies attempting to address such disparities suggest that low-barrier buprenorphine (BUP) treatment models may improve patient engagement and retention in care for marginalized populations. While such models have been studied among persons experiencing houselessness (PEH), less is known about the effects of such treatment models among individuals residing in permanent supportive housing (PSH).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To evaluate the impact of an innovative pharmacist-led pilot service in providing more equitable and accessible BUP treatment to individuals residing in PSH.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This was a 3-month pre-and-post interventional pilot study to evaluate the impact of a novel pharmacist-led outreach service on patient engagement in treatment with BUP for Opioid Use Disorder (OUD). The primary endpoint was treatment adherence, defined as 80% prescription days covered (PDC) in a 3-month period. Secondary endpoints included change in PDC, linkage to office-based care, incidence of overdose, emergency department (ED) presentations, and hospital admissions, as well as successful BUP initiation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Thirty-eight patients were enrolled in the pharmacist-led BUP outreach service. Among the 38 patients, the mean age was 46 years and 16 (42%) were Black. Engagement with the service was associated with increased treatment adherence, with 14 patients (37%) achieving ≥80% PDC post-intervention compared to 1 patient (3%) pre-intervention (<i>p</i> = 0.0009).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>A pharmacist-led BUP outreach service was found to increase treatment adherence in individuals residing in PSH over 3 months. Low-barrier BUP treatment models, such as that evaluated in this study, may help provide more equitable and accessible care that is critical in addressing the socioeconomic and racial disparities in opioid overdose deaths.</p>\u0000 </section>\u0000 </div>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139530407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nationwide evaluation of the clinical impact of acute care adult medicine pharmacists","authors":"Jennifer A. Szwak Pharm.D., FCCP,&nbsp;Rizah Anwar Assadi Pharm.D.,&nbsp;Jimmy Gonzalez Pharm.D.,&nbsp;Lisa T. Hong Pharm.D.,&nbsp;Lyndsi K. Meyenburg Pharm.D.,&nbsp;Andrew R. Miesner Pharm.D.,&nbsp;Taylor Steuber Pharm.D.,&nbsp;Megan Kunka Fritz Pharm.D.","doi":"10.1002/jac5.1916","DOIUrl":"10.1002/jac5.1916","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>The impact of pharmacists has been described for many practice areas including critical care, emergency medicine, and transitions of care. Literature describing the extensive role of adult medicine (AMED) clinical pharmacists in the inpatient setting is limited.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The objective of this study was to characterize clinical activities performed by inpatient AMED pharmacists nationally.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This was a multicenter, prospective, observational study including AMED pharmacists who spend more than 50% of their time practicing in the acute care setting. A 65-item electronic survey was developed and distributed to members of the American College of Clinical Pharmacy AMED Practice and Research Network (PRN). The survey collected demographics, clinical interventions, rates of intervention acceptance, and the significance of those interventions, where applicable. Respondents were asked to report all interventions made over any one-week period while providing direct patient care. Descriptive statistics were used to summarize data. Chi-square tests and Wilcoxon rank sum tests were used to compare nominal and continuous data, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Thirty three pharmacists representing 988.5 h of direct patient care reported activities, including profile review (97%), daily rounding with prescribers (94%), patient education (76%), and order entry or verification (64%). During the study period, 4488 interventions were documented. The most common interventions and activities documented were optimization of therapy (<i>n</i> = 1125, 25%), initiation of therapy (<i>n</i> = 770, 17%), and interpretation of diagnostic data or lab values (<i>n</i> = 331, 7%). The top three therapeutic classes with interventions were antimicrobials (<i>n</i> = 473, 25%), cardiovascular medications (<i>n</i> = 248, 13%), and antithrombotics (<i>n</i> = 190, 10%). Of the applicable interventions, 2775 (89%) were accepted, 2541 (81%) were pharmacist-initiated, and 277 (9%) were classified as serious or very/extremely significant interventions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>AMED pharmacists provide diverse recommendations across numerous medication therapeutic categories that are highly accepted. AMED pharmacists play an important role in optimizing medication use through care team and patient interactions.</p>\u0000","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jac5.1916","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139530280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of single maintenance and reliever therapy (SMART) prescribing of budesonide-formoterol for asthma after a clinical pharmacist-led initiative","authors":"Ila M. Harris Pharm.D., FCCP,&nbsp;Ann M. Philbrick Pharm.D., FCCP,&nbsp;Kristen C. Klemenhagen Ph.D.","doi":"10.1002/jac5.1922","DOIUrl":"10.1002/jac5.1922","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Single maintenance and reliever therapy (SMART) with a combination inhaled corticosteroid-formoterol inhaler is the preferred asthma treatment by the Global Initiative for Asthma and the National Asthma Education and Prevention Program guidelines. These recommendations have been slow to be implemented routinely into clinical practice.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This was an observational cohort study conducted in a family medicine residency program clinic. A clinical pharmacist-led initiative to implement SMART, which included provider education and the development of clinical tools to facilitate SMART prescribing, was assessed. Year 1 (Y1; pre-intervention) and year 2 (Y2; post-intervention) were compared.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Outcomes</h3>\u0000 \u0000 <p>The primary outcome was to evaluate the impact of this initiative on the frequency of SMART (budesonide-formoterol without albuterol) prescribing. Prescription frequencies for albuterol and budesonide-formoterol were also compared separately. Secondary outcomes were Asthma Control Test (ACT) scores and prescribing frequencies among faculty and resident physicians.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The total number of eligible patients in the clinic population was 807, and 459 of these patients met the inclusion criteria. There were more females than males, and the mean age was 39. About 24% had a language preference other than English and 22% required an interpreter. The percentage of patients who were prescribed SMART significantly increased from 0.44% to 11.5% (<i>p</i> &lt; 0.001). Budesonide-formoterol prescriptions increased from 7.4% to 34.6% (<i>p</i> &lt; 0.001). Albuterol metered-dose inhaler prescriptions decreased from 79.7% to 66.2% (<i>p</i> &lt; 0.001). Prescribing patterns were similar for patients of faculty physicians (<i>n</i> = 258) and resident physicians (<i>n</i> = 196). Only 164 (35.7%) patients had an ACT score in Y1 and Y2, and the mean ACT score was not significantly different between Y1 and Y2 (<i>p</i> = 0.973).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>A clinical pharmacist-led SMART asthma prescribing initiative was associated with a significant increase in SMART prescribing, a significant increase in budesonide-formoterol prescribing, and a significant decrease in albuterol prescribing.</p>\u0000 </section>\u0000 </div>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jac5.1922","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139530548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trust, consistency, and positivity: Key elements of success. The 2023 Paul F. Parker medal for distinguished service the profession acceptance speech","authors":"Bradley A. Boucher Pharm.D., FCCP","doi":"10.1002/jac5.1908","DOIUrl":"https://doi.org/10.1002/jac5.1908","url":null,"abstract":"","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139474036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacists and transitions of care","authors":"Madilyn Harris Pharm.D.,&nbsp;Aaron Brown Pharm.D.,&nbsp;Alan J. Zillich Pharm.D., FCCP","doi":"10.1002/jac5.1907","DOIUrl":"https://doi.org/10.1002/jac5.1907","url":null,"abstract":"","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139474037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Essential elements for a nationwide remote pharmacy trainee mentoring program: An opinion of the Ambulatory Care Practice and Research Network of the American College of Clinical Pharmacy","authors":"Sarah E. Wheeler Pharm.D.,&nbsp;Deanna McDanel Pharm.D.,&nbsp;Katie Kiser Pharm.D.,&nbsp;Daniel Majerczyk Pharm.D., FCCP,&nbsp;Julie Ha Nguyen Pharm.D.,&nbsp;Erica F. Crannage Pharm.D.,&nbsp;Taylor Smith Pharm.D.,&nbsp;Melissa Lipari Pharm.D.","doi":"10.1002/jac5.1919","DOIUrl":"10.1002/jac5.1919","url":null,"abstract":"<p>Mentorship is vital for pharmacy trainees to develop professional skills and networks. This paper aims to share the development and implementation of a national remote mentorship program for pharmacy trainees within the American College of Clinical Pharmacy Ambulatory Care Practice and Research Network. We offer recommendations for developing a similar program within organizations emphasizing the program's framework as a resource for similar initiatives. The following key recommendations are proposed to enhance mentorship programs: (1) Program flexibility for tailored interactions; (2) Effective mentor–mentee matching through comprehensive data collection; and (3) Strong, early communication to maintain participant engagement. These strategies are crucial for successfully developing remote mentorship programs in professional pharmacy organizations, as evidenced by limited reports in the current literature.</p>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jac5.1919","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139533886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacy and nursing students' stigma and perceptions toward individuals with mental illness impacted through interaction with a website featuring lived experiences","authors":"Rose Yang,&nbsp;Audrey Long,&nbsp;Becky McDaniel Ph.D.,&nbsp;Megan Orr Ph.D.,&nbsp;Elizabeth Skoy Pharm.D.,&nbsp;Amy Werremeyer Pharm.D.","doi":"10.1002/jac5.1913","DOIUrl":"10.1002/jac5.1913","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Despite its high prevalence and negative impact, mental illness is often sub-optimally treated, in part, due to stigma among health care professionals. Future health care professionals are at the forefront of a potential solution for the provision of stigma-free, equitable mental health care. Innovative approaches to reducing the stigma toward individuals with mental illness are needed. One approach is utilization of the SNAP the Stigma website (www.snapthestigma.com), a collection of photos and reflections by individuals with lived experiences with mental illness.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study was conducted to address the question: Does interacting with the SNAP the Stigma website impact pharmacy and nursing students' perceptions and social distance preference toward an individual with mental illness?</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A pre- and post-survey employed the Bogardus social distance scale (SDS) to assess stigma toward a vignette individual before and after website interaction. In the post-survey, participants reflected on one or more posts from the website that impacted them. A qualitative analysis was performed to identify themes from the responses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A statistically significant reduction in total SDS scores occurred as a result of interaction with SNAP. Three themes were derived including symbolism of mental illness, increased empathy/reduced stereotyping, and lessons regarding what a health care professional can do and offer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>These findings suggest that use of the SNAP website as a stigma-reduction intervention could be a valuable tool for current and future health care professionals to decrease stigma toward those with mental illness and to build intentionality toward empathic and non-discriminatory behavior in health care practice.</p>\u0000 </section>\u0000 </div>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138954918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}